A clear limitation of this study is that it is unlikely that a GIPR agonist or antagonist will be given alone for the treatment of obesity/diabetes as weight loss is modest compared to GLP‐1R agonism. Here, GIPR is linked to obesity due to melanocortin 4 receptor deficiency.